Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections

This study has been terminated.
Information provided by (Responsible Party):
Cubist Pharmaceuticals LLC Identifier:
First received: February 4, 2005
Last updated: July 22, 2016
Last verified: July 2016
This is a Phase 4, randomized, open-label, multicenter, comparative study designed to further evaluate the pharmacokinetics of intravenous (i.v.) daptomycin and the safety and efficacy of daptomycin relative to comparator in the treatment of complicated skin and skin structure infections in patients with renal impairment.

Condition Intervention Phase
Soft Tissue Infections
Drug: daptomycin (up to 14 days)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Phase 4 Trial to Further Evaluate the Pharmacokinetic Profile of Intravenous Daptomycin, and a Comparison of the Safety and Efficacy of Daptomycin Versus Comparator in the Treatment of Adult Patients With Renal Impairment and Complicated Skin and Skin Structure Infections Due, at Least in Part, to Gram-positive Bacteria

Resource links provided by NLM:

Further study details as provided by Cubist Pharmaceuticals LLC:

Primary Outcome Measures:
  • To obtain additional pharmacokinetic data (on dosing days) on intravenous daptomycin in patients with complicated skin and skin structure infections and renal impairment

Secondary Outcome Measures:
  • To compare the safety and efficacy of daptomycin to comparator in patients with complicated skin and skin structure infections and renal impairment at 14 to 21 days after last dose

Estimated Enrollment: 72
Study Start Date: January 2005
Study Completion Date: November 2006
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Inclusion Criteria: - Moderate to end-stage renal impairment - A diagnosis of complicated skin and skin structure infection known or suspected to be due to susceptible Gram-positive bacteria based on positive Gram stain - A diagnosis of bacterial skin and skin structure infection in the presence of some complicating factor Exclusion Criteria: - Known bacteremia, osteomyelitis or endocarditis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00102947

United States, California
Harbor UCLA Medical Center
Torrance, California, United States, 90509
United States, Florida
Tampa General Hospital
Tampa, Florida, United States, 33606
United States, Georgia
Joseph M. Still Research Institute
Augusta, Georgia, United States
United States, Minnesota
Infectious Diseases Minneapolis-LTD
Minneapolis, Minnesota, United States, 55422
United States, New York
Upstate Clinical Research Associates
Buffalo, New York, United States, 14203
University of Rochester Medical Center
Rochester, New York, United States, 14642
United States, North Carolina
AllTrials Clinical Research
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Riverside Methodist Hospital
Columbus, Ohio, United States, 43215
Wright State University/Veterans Affairs Medical Center
Dayton, Ohio, United States, 45428
ID Clinical Research
Toledo, Ohio, United States, 43608
United States, Pennsylvania
St. Luke's Hospital
Bethlehem, Pennsylvania, United States, 19015
The Reading Hospital and Medical Center
West Reading, Pennsylvania, United States, 19610
Sponsors and Collaborators
Cubist Pharmaceuticals LLC
  More Information

Responsible Party: Cubist Pharmaceuticals LLC Identifier: NCT00102947     History of Changes
Other Study ID Numbers: 3009-020
DAP-REN-03-06 ( Other Identifier: Cubist Study Number )
Study First Received: February 4, 2005
Last Updated: July 22, 2016

Keywords provided by Cubist Pharmaceuticals LLC:
renal impairment
complicated skin and skin structure infections

Additional relevant MeSH terms:
Communicable Diseases
Soft Tissue Infections
Anti-Bacterial Agents
Anti-Infective Agents processed this record on May 22, 2017